Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

PURPOSE: There are no established genetic markers for prediction of outcomes after cyclophosphamide (CP)-containing adjuvant therapy for breast cancer. In an ancillary study to a Southwest Oncology Group trial (S8897), we investigated functional polymorphisms in 4 genes in CP pharmacokinetic pathway...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yao, Song, Barlow, William E., Albain, Kathy S., Choi, Ji-Yeob, Zhao, Hua, Livingston, Robert B., Davis, Warren, Rae, James M., Yeh, I-Tien, Hutchins, Laura F., Ravdin, Peter M., Martino, Silvana, Lyss, Alan P., Osborne, C. Kent, Abeloff, Martin, Hortobagyi, Gabriel N., Hayes, Daniel F., Ambrosone, Christine B.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3058716/
https://ncbi.nlm.nih.gov/pubmed/21169260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0281
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars